RedHill Biopharma (RDHL) Depreciation & Amortization (CF) (2016 - 2022)

RedHill Biopharma has reported Depreciation & Amortization (CF) over the past 11 years, most recently at $491000.0 for Q4 2022.

  • Quarterly Depreciation & Amortization (CF) rose 9.35% to $491000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $491000.0 through Dec 2023, down 77.01% year-over-year, with the annual reading at $91000.0 for FY2025, 193.55% up from the prior year.
  • Depreciation & Amortization (CF) was $491000.0 for Q4 2022 at RedHill Biopharma, roughly flat from $491000.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $617000.0 in Q2 2022 and troughed at $22000.0 in Q1 2018.
  • The 5-year median for Depreciation & Amortization (CF) is $433000.0 (2020), against an average of $342350.0.
  • Year-over-year, Depreciation & Amortization (CF) dropped 15.38% in 2018 and then skyrocketed 1209.09% in 2019.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $23000.0 in 2018, then soared by 1000.0% to $253000.0 in 2019, then surged by 86.96% to $473000.0 in 2020, then fell by 5.07% to $449000.0 in 2021, then rose by 9.35% to $491000.0 in 2022.
  • Per Business Quant, the three most recent readings for RDHL's Depreciation & Amortization (CF) are $491000.0 (Q4 2022), $491000.0 (Q3 2022), and $617000.0 (Q2 2022).